Tumor necrosis factor-α-induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 897-901

  Zhu, Li Bing ^a,b   Zhao, Sheng Tao ^c   Xu, Ting Zhao ^b   Wang, He ^d  

^a The People's Liberation Army Mount Lu Sanatorium ^*  (China)

^b FUZHOU GENERAL HOSPITAL   (China)

^c KUNMING GENERAL HOSPITAL   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

A disintegrin and metalloproteinase 10; Apoptosis; Fas ligand; Prostate cancer; Tumor necrosis factor

Indexed keywords

ADAM10 ENDOPEPTIDASE; COMPLEMENTARY DNA; DISINTEGRIN; FAS LIGAND; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA SYNTHESIS; DNA TRANSFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROSTATE CANCER; RNA INTERFERENCE; RNA ISOLATION; WESTERN BLOTTING;

EID: 84892974270     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.1810     Document Type: Article

References (36)

1. Fox JJ, Schöder H and Larson SM: Molecular imaging of prostate cancer. Curr Opin Urol22: 320-327, 2012.
2. Ouyang DY, Xu LH, He XH, etal: Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy9: 20-32, 2013.
3. Hao Y, Zhao Y, Zhao X, etal: Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest29: 318-324, 2011.
4. Damber JE and Aus G: Prostate cancer. Lancet371: 1710-1721, 2008.
5. Eastham JA, May RA, Whatley T, Crow A, Venable DD and Sartor O: Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. JNatl Cancer Instit90: 756-760, 1998.
6. Mononen N and Schleutker J: Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. JUrol181: 1541-1549, 2009.
7. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer: new molecular links. Ann NY Acad Sci1155: 206-221, 2009.
8. Coyle YM: Lifestyle, genes, and cancer. Methods Mol Biol472: 25-56, 2009.
9. Wu H, Haag D, Muley T, etal: Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Genes Chromosomes Cancer52: 250-264, 2013.
10. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature411: 375-379, 2001.
11. López-Otín C and Matrisian LM: Emerging roles of proteases in tumour suppression. Nat Rev Cancer7: 800-808, 2007.
12. Hua H, Li M, Luo T, Yin Y and Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci68: 3853-3868, 2011.
13. Orlichenko LS and Radisky DC: Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis25: 593-600, 2008.
14. Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci98: 621-628, 2007.
15. Rocks N, Paulissen G, El Hour M, etal: Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie90: 369-379, 2008.
16. Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med29: 258-289, 2008.
17. Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev17: 7-30, 2003.
18. Grabowska MM, Sandhu B and Day ML: EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal24: 532-538, 2012.
19. Maretzky T, Scholz F, Köten B, Proksch E, Saftig P and ReissK: ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis. J Invest Dermatol128: 1737-1746, 2008.
20. Schirrmeister W, Gnad T, Wex T, etal: Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection. Exp Cell Res315: 3500-3508, 2009.
21. Arima T, Enokida H, Kubo H, etal: Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Science98: 1720-1726, 2007.
22. 2+/p38alpha MAPK-mediated activation of c-Jun and ATF-2 pathways. IntJBiochem Cell Biol42: 1498-1506, 2010.
23. McCulloch DR, Akl P, Samaratunga H, Herington AC and Odorico DM: Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factorI, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res10: 314-323, 2004.
24. Blobel CP: ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol6: 32-43, 2005.
25. Lamour NF, Wijesinghe DS, Mietla JA, Ward KE, Stahelin RV and Chalfant CE: Ceramide kinase regulates the production of tumor necrosis factor alpha (TNFalpha) via inhibition of TNFα-converting enzyme. J Biol Chem286: 42808-42817, 2011.
26. Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol4: 565-573, 2003.
27. Cuadrado A and Nebreda AR: Mechanisms and functions of p38MAPK signalling. Biochem J429: 403-417, 2010.
28. Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev75: 50-83, 2011.
29. Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest139: 1470-1479, 2011.
30. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature441: 431-436, 2006.
31. Bhoj VG and Chen ZJ: Ubiquitylation in innate and adaptive immunity. Nature458: 430-437, 2009.
32. Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol5: 749-759, 2005.
33. Strasser A, Jost PJ and Nagata S: The many roles of FAS receptor signaling in the immune system. Immunity30: 180-192, 2009.
34. Krammer PH: CD95's deadly mission in the immune system. Nature407: 789-795, 2000.
35. Villa-Morales M and Fernández-Piqueras J: Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets16: 85-101, 2012.
36. Liu WH and Chang LS: Fas/FasL-dependent and-independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol43: 1708-1719, 2011.